- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Injections of erenumab.
Migraine prophylaxis in adults experiencing at least 4 migraine days per month.
70mg every 4 weeks.
Some patients may benefit from an increased dose of 140mg every 4 weeks.
For subcutaneous injection only.
Administered into the abdomen, thigh or outer area of the upper arm (the arm should only be used if administered by a person other than the patient).
Children under 18 years
Precautions and Warnings
Decreased gastrointestinal motility
Severe cardiovascular disorder
Treatment to be initiated by specialist
Needle cover contains a derivative of latex
Avoid injection into broken or bruised skin
Advise patient to report constipation
Monitor for constipation; give laxatives as required
Discontinue if an adequate response not achieved within 3 months
Discontinue if significant constipation occurs, until resolved
Response to treatment should be reviewed after 3 months and in those showing clinical benefit, at regular intervals thereafter.
Constipation has been reported with the use of erenumab, the majority of cases are reported after the first dose of erenumab, other cases have also been reported later in the treatment. In most cases constipation resolved within three months. Severe constipation requiring hospitalisation have also been reported. Advise patient to report worsening constipation. Consider discontinuation if severe constipation occurs.
Pregnancy and Lactation
Use erenumab with caution during pregnancy.
The manufacturer does not recommend using erenumab during pregnancy. At the time of writing there is limited published information regarding the use of erenumab during pregnancy. Potential risks are unknown.
Use erenumab with caution in breastfeeding.
The manufacturer advises caution if erenumab is used when breastfeeding. The presence of erenumab in human breast milk is unknown but due to its large molecular weight, transfer is not expected. Effects on exposed infants are unknown.
Development of neutralising antibodies
Erythema at injection site
Injection site reactions
Itching (injection site)
Local pain (injection site)
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: September 2019
Summary of Product Characteristics: Aimovig 70mg & 140mg solution for injection in pre-filled pen. Novartis Pharmaceuticals. Revised August 2020.
US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
Available at: https://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT
Erenumab Last revised: 03 December 2018
Last accessed: 12 September 2019
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.